Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada.
Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada.
复制标题
DOI：
10.1186/s12879-016-1748-z
复制
发表时间：
2016-08-11
影响因子：
3.7
通讯作者：
Drews S
中科院分区：
文献类型：
--
作者：
Fathima S;Simmonds K;Invik J;Scott AN;Drews S
人副流感病毒（hPIV）可导致婴儿和成人严重的呼吸道疾病。我们的研究使用回顾性实验室、管理和公共卫生数据描述了hPIV 1 -4与毛细支气管炎、哮吼和肺炎的相关性。由于一些商业呼吸道病毒检测板中历史上缺乏hPIV 4等问题，hPIV 4对人群水平的哮吼、细支气管炎和肺炎影响的描述通常有限。本研究将使用常规临床实验室数据和管理数据，初步描述hPIV 4对我们人群中这些疾病的影响。将hPIV阳性患者的三年队列与医生访视和住院数据相关联，以定义病例和住院状态。使用国际疾病分类（ICD-9）代码确定病例是否患有哮吼、细支气管炎和肺炎。我们还研究了hPIV 1 -4之间住院状态、年龄和性别的差异。使用SPSS（版本19.0.0，IBM Corp© 2010）和Graphpad Prism V6（GraphPad Software，Inc.，2012年）。仅hPIV 1和hPIV 4标本的阳性率高于所有送去进行呼吸道病毒检测的标本的5%。hPIV 1表现出两年一次的模式，而hPIV 3的模式由于阳性率较低而难以解释。由于这些标本的阳性率较低，因此未评估hPIV 2和hPIV 4的循环模式。2010年至2013年，共有2300例hPIV病例，其中hPIV 3（46%）最常见，其次是hPIV 1（27%）、hPIV 4（16%）和hPIV 2（11%）。所有hPIV类型的中位年龄为2岁。hPIV 1和hPIV 2的雄性略多于雌性，hPIV 3的分布相等，hPIV 4的雌性略多于雄性。hPIV 1和hPIV 2引起哮吼的比例最高，hPIV 3和hPIV 4引起肺炎的比例最高。hPIV 4病例的疾病分布为：肺炎（21%，95% CI 17.1-25.7），细支气管炎（18%，95% CI 14.3-22.5），哮吼（2%，95% CI 0.8-3.9），肺炎、细支气管炎或哮吼中任何一种的混合疾病（4%，95% CI 2.5-7.0）或其他呼吸系统疾病（54%，95% CI 49.1-59.6）。我们使用实验室和管理数据对hPIV 1 -4与哮吼、细支气管炎和肺炎的相关性进行描述性分析。在我们的人群中，hPIV 4似乎与细支气管炎和肺炎相关性更高，与哮吼相关性更低。
Human Parainfluenza Virus (hPIV) causes severe respiratory illness in infants and adults. Our study describes the association of hPIV1–4 with bronchiolitis, croup, and pneumonia using retrospective laboratory, administrative and public health data. Due to issues including the historic lack of hPIV4 in some commercial respiratory virus panels, the description of the impact of hPIV4 on croup, bronchiolitis, and pneumonia at population levels has often been limited. This study will use routine clinical laboratory data, and administrative data to provide a preliminary description of the impact of hPIV4 on these diseases in our population. A three year cohort of patients positive for hPIV was linked with data from physician visits and hospital admissions to define cases and hospitalization status. International Classification of Disease (ICD-9) codes were used to determine if cases had croup, bronchiolitis, and pneumonia. We also looked at differences in hospitalization status, age and gender among hPIV1–4. All statistical analysis was done using SPSS (Version 19.0.0, IBM Corp© 2010) and Graphpad Prism V6 (GraphPad Software, Inc., 2012). Only hPIV1 and hPIV4 specimens had positivity rates greater than 5 % of all specimens sent for respiratory virus panel testing. hPIV1 exhibited a biennial pattern while the pattern for hPIV3 was less interpretable due to lower positivity rates. Circulation patterns for hPIV2 and hPIV4 were not assessed due to the low positivity rates of theses specimens. From 2010 to 2013, there were 2300 hPIV cases with hPIV3 (46 %) being the most common, followed by hPIV1 (27 %), hPIV4 (16 %) and hPIV2 (11 %). The median age was 2 years for all hPIV types. Males were slightly greater than females for hPIV1 and hPIV2, with an equal distribution for hPIV3 and slightly more females than males for hPIV4. hPIV1 and hPIV2 had the highest or proportion of croup while hPIV3 and hPIV4 had the highest proportion of pneumonia. Within hPIV4 cases, distributions of diseases were; pneumonia (21 %, 95 % CI 17.1–25.7), bronchiolitis (18 %, 95 % CI 14.3–22.5), croup (2 %, 95 % CI 0.8–3.9), mixed illness of any of pneumonia, bronchiolitis or croup (4 %, 95 % CI 2.5–7.0) or other respiratory diseases (54 %, 95 % CI 49.1–59.6). We used laboratory and administrative data to undertake a descriptive analysis of the association of hPIV1–4 with croup, bronchiolitis and pneumonia. hPIV4 appears to be more associated more with bronchiolitis and pneumonia and less with croup in our population.